Charlson comorbidity index as a predictor of overall survival for patients with early stage NSCLC?

Introduction: The competing comorbidity in patients with early-stage non-small cell lung cancer (NSCLC) might be used as a predictor of overall survival (OS). Objectives: The study goal was to utilize a validated comorbidity scoring system to determine its impact on OS. Methods: A database of 189 patients with NSCLC treated with stereotactic body radiotherapy (SBRT) from 2005 to 2014 was reviewed. Data of a control group of 33 untreated patients was extracted from the DLCR from 2000 to 2012 (table 1 baseline characteristics). Charlson Comorbidity Index (CCI) was calculated by physician chart review with lung cancer being excluded from the scoring. Treated and untreated patients were dichotomized into 2 groups by CCI, moderate CCI